Aerovate Therapeutics is a US-based biopharmaceutical company that develops drugs for rare cardiopulmonary diseases. Its main focus is AV-101, a dry powder inhaled formula designed to treat pulmonary arterial hypertension, currently undergoing Phase 2b/Phase 3 trial. Founded in 2018, Aerovate Therapeutics is headquartered in Waltham, Massachusetts.